Abstract
Neonatal stroke leads to mortality and severe morbidity, but there is no effective treatment currently available. Erythropoietin (EPO) has been shown to promote cytoprotection and neurogenesis and decrease subventricular zone morphologic changes following brain injury. The long-term cellular response to EPO has not been defined, and local changes in cell fate decision may play a role in functional improvement. We performed middle cerebral artery occlusion in P10 rats. EPO treatment (5 U/g i.p.) significantly preserved hemispheric brain volume 6 weeks after injury. Furthermore, EPO increased the percentage of newly generated neurons while decreasing newly generated astrocytes following brain injury, without demonstrating long-term differences in the subventricular zone. These results suggest that EPO may neuroprotect and direct cell fate toward neurogenesis and away from gliogenesis in neonatal stroke.
2007 S. Karger AG, Basel
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Animals, Newborn
-
Astrocytes / drug effects
-
Astrocytes / physiology
-
Cell Differentiation / drug effects
-
Cell Differentiation / physiology
-
Cell Proliferation / drug effects*
-
Erythropoietin / pharmacology*
-
Erythropoietin / therapeutic use
-
Gliosis / prevention & control
-
Hypoxia, Brain / drug therapy*
-
Hypoxia, Brain / pathology
-
Hypoxia, Brain / physiopathology
-
Infarction, Middle Cerebral Artery / drug therapy
-
Infarction, Middle Cerebral Artery / pathology
-
Infarction, Middle Cerebral Artery / physiopathology
-
Nerve Regeneration / drug effects
-
Nerve Regeneration / physiology
-
Neurons / drug effects
-
Neurons / physiology
-
Neuroprotective Agents / pharmacology*
-
Neuroprotective Agents / therapeutic use
-
Rats
-
Rats, Sprague-Dawley
-
Recovery of Function / drug effects
-
Recovery of Function / physiology
-
Stem Cells / drug effects
-
Stem Cells / physiology
-
Stroke / drug therapy*
-
Stroke / pathology
-
Stroke / physiopathology
-
Time
-
Treatment Outcome
Substances
-
Neuroprotective Agents
-
Erythropoietin